查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
最小殘留疾病檢測市場規模,份額和趨勢分析報告：按技術（NGS,PCR）,癌症類型（血液系統惡性腫瘤）,最終用途（醫院）,地區,細分市場預測2023-2030
市場調查報告書
商品編碼
1178627

最小殘留疾病檢測市場規模,份額和趨勢分析報告：按技術（NGS,PCR）,癌症類型（血液系統惡性腫瘤）,最終用途（醫院）,地區,細分市場預測2023-2030

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), Cancer Type (Hematological Malignancy), By End-use (Hospitals), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

最小殘留病檢測市場增長和趨勢

根據 Grand View Research, Inc. 的最新報告，到 2030 年，全球微小殘留病檢測市場預計將達到 45 億美元，2023 年至 2030 年的複合年增長率為 11.45%。採用 MRD 測試作為一種新的診斷和預後測定已經產生了用於治療所有類型的血液惡性腫瘤的緊密定制的治療方案。 結果測量對於成功採用給定的癌症治療方案至關重要。

MRD 產生重要的分子信息，以更好地了解癌症狀態並最終利用治療結果。 因此，MRD 測試越來越多地用作基於腫瘤學研究的眾多臨床試驗研究中的終點分析步驟，並且還有效地記錄了由於個體遺傳特徵而導致的治療結果的變化。。 例如，2020 年 11 月，Adaptive Biotechnologies Corporation 與 GlaxoSmithKline plc. 展開合作，使用他們的 clonoSEQ 分析來評估 GSK 血液療法治療後殘留的癌細胞。

手術切除腫瘤與其他治療相結合併不能完全去除癌細胞。 癌症的痕跡可能會留在身體的某些部位或血液中。 診斷這些殘留細胞對於確定未來是否需要化療或放療非常重要。 研究人員正在設計非侵入性測試以有效檢測 MRD。 例如，2022 年 2 月，C2i Genomics 血液測試對腫瘤手術治療後殘留的癌細胞進行了量化。 C2inform 測試還具有 CE 標誌許可，並在歐洲作為“軟件即醫療設備”MRD 測試提供。

腫瘤藥物根據臨床證據進行有效調節以防止腫瘤細胞持續存在，並根據個體的特定進展情況進行個體化。 許多研究增加了考慮個體遺傳特徵以進行有效治療的必要性。 例如，2022 年 10 月，Adaptive Biotechnologies Corporation 與 Epic 合作，以增加對血癌 MRD 監測的訪問。 此外，2021 年 2 月，Natera Inc. 與 Personalis Inc. 合作，為 NeXT 腫瘤分析（Personalis）和個性化 ctDNA 平台 Signatera 診斷產品（Natera, Inc.）有效設計治療監測制度和 MRD 評估，以了解結果通過整合實現個性化的癌症護理。

微小殘留病檢測市場報告要點

MRD檢測的高靈敏度和廣泛適用性使流式細胞儀在2022年主導微小殘留病檢測市場

由於血液系統惡性腫瘤的患病率不斷增加，預計血液系統惡性腫瘤部分在預測期內將以最快的速度增長

由於醫院和專科診所擁有先進的診斷設備和熟練的專業人員，醫院和專科診所部門將成為 2022 年收入最高的部門

由於該地區血液系統惡性腫瘤的患病率上升以及報銷環境的改善，北美將在 2022 年主導微小殘留病檢測市場

>

內容

第一章調查方法及範圍

  • 市場細分
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • 次要信息
    • 初步調查
    • 初步調查的詳細信息
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
  • 全球市場：CAGR 計算
  • 調查假設
  • 次要信息列表
  • 主要信息列表
  • 目的
  • 縮寫列表

第 2 章執行摘要

  • 市場概況
  • 片段快照
  • 競爭格局快照

第 3 章市場變量、趨勢和範圍

  • 最小殘留病檢測市場譜系展望
    • 母公司市場展望
      • 細胞健康篩查市場展望
      • 體外診斷市場前景
  • 描繪滲透率和增長前景
  • 市場驅動因素分析
    • 癌症患病率增加
    • 增加對 MRD 測試的投資
    • 增加研究投資
  • 市場製約因素分析
    • 與 MRD 檢查相關的高成本
    • 與 MRD 測試相關的複雜監管框架
  • SWOT 分析，按因素（政治和法律、經濟、技術）
  • 波特的五力分析
  • 監管框架

第 4 章最小殘留疾病檢測市場-細分分析，按技術，2018-2030 年（百萬美元）

  • 定義和範圍
  • 最小殘留病檢測市場：技術波動分析
    • 流式細胞儀
    • 聚合□鍊式反應 (PCR)
    • 下一代測序 (Ngs)
    • 其他

第 5 章最小殘留疾病檢測市場 - 細分分析，按癌症類型，2018-2030（百萬美元）

  • 微小殘留病檢測市場：癌症類型的變異分析
    • 血液系統惡性腫瘤
    • 實體瘤

第 6 章最小殘留疾病檢測市場 - 細分分析，按業務劃分，2018-2030 年（百萬美元）

  • 定義和範圍
  • 微小殘留病檢測市場：業務波動分析
    • 醫院和專科診所
    • 診斷實驗室
    • 學術研究機構
    • 其他

第 7 章最小殘留病檢測市場-區域業務分析

  • 定義和範圍
  • 2022 年和 2030 年區域市場份額分析
  • 區域市場儀表板
  • 區域市場概況
  • SWOT 分析，按因素（政治和法律、經濟和技術）
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 多邊環境協定
  • 2022-2030 年市場規模、預測、趨勢分析
  • 北美
    • 美國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 加拿大
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
  • 歐洲
    • 英國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 德國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 西班牙
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 法國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 意大利
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 丹麥
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 瑞典
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 挪威
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
  • 亞太地區
    • 日本
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 中國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 印度
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 韓國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 泰國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 澳大利亞
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
  • 拉丁美洲
    • 巴西
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 墨西哥
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 阿根廷
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
  • 多邊環境協定
    • 南非
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 沙特阿拉伯
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景
    • 科威特
      • 主要國家動力學
      • 監管框架
      • 競爭場景
      • 最近的發展
      • 投資場景

第 8 章最小殘留病檢測市場-競爭分析

  • 公司/競爭對手分類（主要創新者、市場領導者、初創企業）
  • 戰略框架
  • 市場參與分類
  • 主要市場進入者的近期趨勢和影響分析
  • 公司定位分析
  • 分銷商名單
    • 主要客戶
    • 上市公司
    • 私人公司

第九章公司簡介

  • 公司簡介
    • EXACT SCIENCES CORPORATION,
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • GRAIL, LLC
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • VERACYTE, INC.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • NATERA, INC.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • GUARDANT HEALTH
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • F. HOFFMANN-LA ROCHE LTD
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • FOUNDATION MEDICINE, INC.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • QIAGEN
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • MDXHEALTH
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • BIO-TECHNE.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68040-016-3

Minimal Residue Disease Testing Market Growth & Trends:

The global minimal residual disease testing market size is expected to reach USD 4.50 billion by 2030, at a CAGR of 11.45% from 2023 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

  • The flow cytometry segment held a dominant share in the minimal residual disease testing market in 2022 owing to the high sensitivity and wide applicability of MRD testing
  • The hematological malignancy segment is projected to grow at the fastest rate over the forecast period owing to the increasing prevalence of hematological malignancy
  • The hospitals and specialty clinics segment is the highest revenue-generating segment in 2022 owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics
  • North America dominated the minimal residual disease testing market in 2022, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Secondary Sources
    • 1.3.3 Primary Research
    • 1.3.4 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Minimal Residual Disease Testing Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
      • 3.1.1.1 Cellular Health Screening Market Outlook
      • 3.1.1.2 In Vitro Diagnostics Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Market Driver Analysis
    • 3.3.1 Increasing Prevalence Of Cancer
    • 3.3.2 Growing Investments In Mrd Testing
    • 3.3.3 Growing Investment For Research
  • 3.4 Market Restraint Analysis
    • 3.4.1 High-Cost Associated With Mrd Testing
    • 3.4.2 Complex Regulatory Framework Associated With Mrd Testing
  • 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
  • 3.6 Porter's Five Forces Analysis
  • 3.7 Regulatory Framework

Chapter 4 Minimal Residual Disease Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)

  • 4.1 Definition And Scope
  • 4.2 Minimal Residual Disease Testing Market: Technology Movement Analysis
    • 4.2.1 Flow Cytometry
      • 4.2.1.1 Flow Cytometry Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.2 Polymerase Chain Reaction (Pcr)
      • 4.2.2.1 Polymerase Chain Reaction (Pcr) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.3 Next Generation Sequencing (Ngs)
      • 4.2.3.1 Next Generation Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.4 Others
      • 4.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Minimal Residual Disease Testing Market - Segment Analysis, By Cancer Type, 2018 - 2030 (USD Million)

  • 5.1 Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
    • 5.1.1 Hematological Malignancy
      • 5.1.1.1 Hematological Malignancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Solid Tumors
      • 5.1.2.1 Solid Tumors Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Minimal Residual Disease Testing Market - Segment Analysis, By Business, 2018 - 2030 (USD Million)

  • 6.1 Definition And Scope
  • 6.2 Minimal Residual Disease Testing Market: Business Movement Analysis
    • 6.2.1 Hospitals And Speciality Clinics
      • 6.2.1.1 Hospitals And Speciality Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 Diagnostic Laboratories
      • 6.2.2.1 Diagnostic Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.3 Academic And Research Institutes
      • 6.2.3.1 Research Institutes Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.4 Others
      • 6.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Minimal Residual Disease Testing Market - Regional Business Analysis

  • 7.1 Definition & Scope
  • 7.2 Regional Market Share Analysis, 2022 & 2030
  • 7.3 Regional Market Dashboard
  • 7.4 Regional Market Snapshot
  • 7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 7.5.1 North America
    • 7.5.2 Europe
    • 7.5.3 Asia Pacific
    • 7.5.4 Latin America
    • 7.5.5 MEA
  • 7.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
  • 7.7 North America
    • 7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD MILLION)
    • 7.7.2 U.S.
      • 7.7.2.1 U.S. Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.7.2.2 Key country Dynamics
      • 7.7.2.3 Regulatory Framework
      • 7.7.2.4 Competitive Scenario
      • 7.7.2.5 Recent Developments
      • 7.7.2.6 Investments Scenario
    • 7.7.3 Canada
      • 7.7.3.1 Canada Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.7.3.2 Key country Dynamics
      • 7.7.3.3 Regulatory Framework
      • 7.7.3.4 Competitive Scenario
      • 7.7.3.5 Recent Developments
      • 7.7.3.6 Investments Scenario
  • 7.8 Europe
    • 7.8.1 Europe Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.2 UK
      • 7.8.2.1 UK Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.2.2 Key country Dynamics
      • 7.8.2.3 Regulatory Framework
      • 7.8.2.4 Competitive Scenario
      • 7.8.2.5 Recent Developments
      • 7.8.2.6 Investments Scenario
    • 7.8.3 Germany
      • 7.8.3.1 Germany Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.3.2 Key country Dynamics
      • 7.8.3.3 Regulatory Framework
      • 7.8.3.4 Competitive Scenario
      • 7.8.3.5 Recent Developments
      • 7.8.3.6 Investments Scenario
    • 7.8.4 Spain
      • 7.8.4.1 Spain Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.4.2 Key country Dynamics
      • 7.8.4.3 Regulatory Framework
      • 7.8.4.4 Competitive Scenario
      • 7.8.4.5 Recent Developments
      • 7.8.4.6 Investments Scenario
    • 7.8.5 France
      • 7.8.5.1 France Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.5.2 Key country Dynamics
      • 7.8.5.3 Regulatory Framework
      • 7.8.5.4 Competitive Scenario
      • 7.8.5.5 Recent Developments
      • 7.8.5.6 Investments Scenario
    • 7.8.6 Italy
      • 7.8.6.1 Italy Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.6.2 Key country Dynamics
      • 7.8.6.3 Regulatory Framework
      • 7.8.6.4 Competitive Scenario
      • 7.8.6.5 Recent Developments
      • 7.8.6.6 Investments Scenario
    • 7.8.7 Denmark
      • 7.8.7.1 Denmark Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.7.2 Key country Dynamics
      • 7.8.7.3 Regulatory Framework
      • 7.8.7.4 Competitive Scenario
      • 7.8.7.5 Recent Developments
      • 7.8.7.6 Investments Scenario
    • 7.8.8 Sweden
      • 7.8.8.1 Sweden Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.8.2 Key country Dynamics
      • 7.8.8.3 Regulatory Framework
      • 7.8.8.4 Competitive Scenario
      • 7.8.8.5 Recent Developments
      • 7.8.8.6 Investments Scenario
    • 7.8.9 Norway
      • 7.8.9.1 Norway Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.9.2 Key country Dynamics
      • 7.8.9.3 Regulatory Framework
      • 7.8.9.4 Competitive Scenario
      • 7.8.9.5 Recent Developments
      • 7.8.9.6 Investments Scenario
  • 7.9 Asia Pacific
    • 7.9.1 Asia-Pacific Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.2 Japan
      • 7.9.2.1 Japan Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.2.2 Key country Dynamics
      • 7.9.2.3 Regulatory Framework
      • 7.9.2.4 Competitive Scenario
      • 7.9.2.5 Recent Developments
      • 7.9.2.6 Investments Scenario
    • 7.9.3 China
      • 7.9.3.1 China Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.3.2 Key country Dynamics
      • 7.9.3.3 Regulatory Framework
      • 7.9.3.4 Competitive Scenario
      • 7.9.3.5 Recent Developments
      • 7.9.3.6 Investments Scenario
    • 7.9.4 India
      • 7.9.4.1 India Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.4.2 Key country Dynamics
      • 7.9.4.3 Regulatory Framework
      • 7.9.4.4 Competitive Scenario
      • 7.9.4.5 Recent Developments
      • 7.9.4.6 Investments Scenario
    • 7.9.5 South Korea
      • 7.9.5.1 South Korea Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.5.2 Key country Dynamics
      • 7.9.5.3 Regulatory Framework
      • 7.9.5.4 Competitive Scenario
      • 7.9.5.5 Recent Developments
      • 7.9.5.6 Investments Scenario
    • 7.9.6 Thailand
      • 7.9.6.1 Thailand Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.6.2 Key country Dynamics
      • 7.9.6.3 Regulatory Framework
      • 7.9.6.4 Competitive Scenario
      • 7.9.6.5 Recent Developments
      • 7.9.6.6 Investments Scenario
    • 7.9.7 Australia
      • 7.9.7.1 Australia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.7.2 Key country Dynamics
      • 7.9.7.3 Regulatory Framework
      • 7.9.7.4 Competitive Scenario
      • 7.9.7.5 Recent Developments
      • 7.9.7.6 Investments Scenario
  • 7.10 Latin America
    • 7.10.1 Latin America Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.10.2 Brazil
      • 7.10.2.1 Brazil Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.10.2.2 Key country Dynamics
      • 7.10.2.3 Regulatory Framework
      • 7.10.2.4 Competitive Scenario
      • 7.10.2.5 Recent Developments
      • 7.10.2.6 Investments Scenario
    • 7.10.3 Mexico
      • 7.10.3.1 Mexico Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.10.3.2 Key country Dynamics
      • 7.10.3.3 Regulatory Framework
      • 7.10.3.4 Competitive Scenario
      • 7.10.3.5 Recent Developments
      • 7.10.3.6 Investments Scenario
    • 7.10.4 Argentina
      • 7.10.4.1 Argentina Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.10.4.2 Key country Dynamics
      • 7.10.4.3 Regulatory Framework
      • 7.10.4.4 Competitive Scenario
      • 7.10.4.5 Recent Developments
      • 7.10.4.6 Investments Scenario
  • 7.11 MEA
    • 7.11.1 MEA Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.11.2 South Africa
      • 7.11.2.1 South Africa Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.2.2 Key country Dynamics
      • 7.11.2.3 Regulatory Framework
      • 7.11.2.4 Competitive Scenario
      • 7.11.2.5 Recent Developments
      • 7.11.2.6 Investments Scenario
    • 7.11.3 Saudi Arabia
      • 7.11.3.1 Saudi Arabia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.3.2 Key country Dynamics
      • 7.11.3.3 Regulatory Framework
      • 7.11.3.4 Competitive Scenario
      • 7.11.3.5 Recent Developments
      • 7.11.3.6 Investments Scenario
    • 7.11.4 UAE
      • 7.11.4.1 UAE Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.4.2 Key country Dynamics
      • 7.11.4.3 Regulatory Framework
      • 7.11.4.4 Competitive Scenario
      • 7.11.4.5 Recent Developments
      • 7.11.4.6 Investments Scenario
    • 7.11.5 Kuwait
      • 7.11.5.1 Kuwait Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.5.2 Key country Dynamics
      • 7.11.5.3 Regulatory Framework
      • 7.11.5.4 Competitive Scenario
      • 7.11.5.5 Recent Developments
      • 7.11.5.6 Investments Scenario

Chapter 8 Minimal Residual Disease Testing Market - Competitive Analysis

  • 8.1 Company/Competition Categorization (Key Innovators, Market leaders, Emerging Players)
  • 8.2 Strategy Framework
  • 8.3 Market Participation Categorization
  • 8.4 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.5 Company Position Analysis
  • 8.6 List of Distributors
    • 8.6.1 Key Customers
    • 8.6.2 Public Companies
    • 8.6.3 Private Companies

Chapter 9 Company Profiles

  • 9.1 Company Profiles
    • 9.1.1 EXACT SCIENCES CORPORATION,
      • 9.1.1.1 Company Overview
      • 9.1.1.2 Financial Performance
      • 9.1.1.3 Product Benchmarking
      • 9.1.1.4 Strategic Initiatives
    • 9.1.2 GRAIL, LLC
      • 9.1.2.1 Company Overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Product Benchmarking
      • 9.1.2.4 Strategic Initiatives
    • 9.1.3 VERACYTE, INC.
      • 9.1.3.1 Company Overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Product Benchmarking
      • 9.1.3.4 Strategic Initiatives
    • 9.1.4 NATERA, INC.
      • 9.1.4.1 Company Overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Product Benchmarking
      • 9.1.4.4 Strategic Initiatives
    • 9.1.5 GUARDANT HEALTH
      • 9.1.5.1 Company Overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Product Benchmarking
      • 9.1.5.4 Strategic Initiatives
    • 9.1.6 F. HOFFMANN-LA ROCHE LTD
      • 9.1.6.1 Company Overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Product Benchmarking
      • 9.1.6.4 Strategic Initiatives
    • 9.1.7 FOUNDATION MEDICINE, INC.
      • 9.1.7.1 Company Overview
      • 9.1.7.2 Financial performance
      • 9.1.7.3 Product Benchmarking
      • 9.1.7.4 Strategic Initiatives
    • 9.1.8 QIAGEN
      • 9.1.8.1 Company Overview
      • 9.1.8.2 Financial performance
      • 9.1.8.3 Product Benchmarking
      • 9.1.8.4 Strategic Initiatives
    • 9.1.9 MDXHEALTH
      • 9.1.9.1 Company Overview
      • 9.1.9.2 Financial performance
      • 9.1.9.3 Product Benchmarking
      • 9.1.9.4 Strategic Initiatives
    • 9.1.10 BIO-TECHNE.
      • 9.1.10.1 Company Overview
      • 9.1.10.2 Financial performance
      • 9.1.10.3 Product Benchmarking
      • 9.1.10.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 7 Global Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 11 North America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 13 U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 18 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 20 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 21 Europe Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 22 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 23 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 24 UK Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 25 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 28 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 29 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 30 France Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 31 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 37 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 38 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 40 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 41 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 43 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 44 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 45 Norway Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 50 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 53 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 54 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 55 China Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 56 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 60 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 62 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 64 India Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 65 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 66 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 67 South Korea Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 68 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 70 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 72 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 73 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 81 MEA Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 MEA Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 83 MEA Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 84 MEA Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Gastroesophageal Reflux Disease Therapeutics Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping
  • Fig. 15 Minimal residual disease testing market: Technology outlook and key takeaways
  • Fig. 16 Minimal residual disease testing market: Technology movement analysis & market share 2022 & 2030
  • Fig. 17 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Polymerase chain reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Next generation sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Minimal residual disease testing market: Cancer type outlook and key takeaways
  • Fig. 22 Minimal residual disease testing market: Cancer type movement analysis & market share 2022 & 2030
  • Fig. 23 Haematological malignancy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Minimal residual disease testing market: End-Use outlook and key takeaways
  • Fig. 26 Minimal residual disease testing market: End-Use movement analysis & market share 2022 & 2030
  • Fig. 27 Hospitals and specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Academic and research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Marketplace: Key Takeaways
  • Fig. 32 Regional Outlook, 2022 & 2030
  • Fig. 33 Regional Market Dashboard
  • Fig. 34 Regional Market Place: Key Takeaways
  • Fig. 35 North America, SWOT Analysis
  • Fig. 36 Europe, SWOT Analysis
  • Fig. 37 Asia Pacific, SWOT Analysis
  • Fig. 38 Latin America, SWOT Analysis
  • Fig. 39 MEA, SWOT Analysis
  • Fig. 40 North America
  • Fig. 41 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 U.S.
  • Fig. 43 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Canada
  • Fig. 45 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Europe
  • Fig. 47 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 UK
  • Fig. 49 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Germany
  • Fig. 51 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 France
  • Fig. 53 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Italy
  • Fig. 55 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Spain
  • Fig. 57 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark
  • Fig. 59 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden
  • Fig. 61 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Norway
  • Fig. 63 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Asia Pacific
  • Fig. 65 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Japan
  • Fig. 67 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 68 China
  • Fig. 69 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 70 India
  • Fig. 71 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Australia
  • Fig. 73 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand
  • Fig. 75 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea
  • Fig. 77 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America
  • Fig. 79 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Brazil
  • Fig. 81 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Mexico
  • Fig. 83 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina
  • Fig. 85 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 86 MEA
  • Fig. 87 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 88 South Africa
  • Fig. 89 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia
  • Fig. 91 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 92 UAE
  • Fig. 93 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Kuwait
  • Fig. 95 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Strategy Mapping